Table 1.
Significant TERT regulators of PCa compared to normal prostate tissue and vice versa.
| Regulators Tumor | Frequency Tumor (n = 300 Models) | Frequency Normal (n = 300 Models) | p-Value ** |
|---|---|---|---|
| PITX1 * | 186 (62%) | 35 (12%) | 1.56 × 10−37 |
| MITF * | 119 (40%) | 28 (9%) | 5.97 × 10−17 |
| AR * | 92 (31%) | 21 (7%) | 1.26 × 10−12 |
| TFAP2C * | 72 (24%) | 11 (4%) | 1.67 × 10−12 |
| E2F2 * | 92 (31%) | 24 (8%) | 1.31 × 10−11 |
| NR2F2 * | 97 (32%) | 27 (9%) | 1.31 × 10−11 |
| SMARCB1 | 88 (29%) | 24 (8%) | 1.15 × 10−10 |
| CEBPA * | 65 (22%) | 20 (7%) | 6.08 × 10−7 |
| BHLHE40 * | 53 (18%) | 16 (5%) | 8.26 × 10−6 |
| CTCF * | 48 (16%) | 15 (5%) | 4.13 × 10−5 |
| ETS1 * | 63 (21%) | 26 (9%) | 7.43 × 10−5 |
| MXI1 | 27 (9%) | 5 (2%) | 1.75 × 10−4 |
| POLR2A | 34 (11%) | 9 (3%) | 2.23 × 10−4 |
| RAD21 | 32 (11%) | 11 (4%) | 2.37 × 10−3 |
| IRF1 * | 31 (10%) | 12 (4%) | 6.38 × 10−3 |
| TFAP2D * | 34 (11%) | 18 (6%) | 3.91 × 10−2 |
| MAX | 36 (12%) | 20 (7%) | 4.62 × 10−2 |
* marked TF were predicted as TERT regulators specifically for prostate cancer in a previous study of us [17]. ** adjusted for multiple testing correction (Benjamini-Hochberg).